SWOG Cancer Research Network Clinical Trial Pipeline: 58 Active Trials, 10 Changes This Month

9 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 7 with minor changes only.

Notable

Standard Systemic Therapy With or Without Definitive Treatment · Metastatic Prostate Cancer

Primary completion pushed from Apr 1, 2028 to Apr 1, 2033

Also in this update: Completion pushed from Oct 1, 2031 to Oct 1, 2036

SWOG Cancer Research NetworkPhase 3 NCT03678025 Registry history of NCT03678025 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Notable

DRAMMATIC · S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Primary completion pushed from Jul 1, 2029 to Sep 2032

SWOG Cancer Research NetworkPhase 3 NCT04071457 Registry history of NCT04071457 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026

Show 7 trials with minor changes only

Minor

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment · Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Trial sites expanded: 386 → 413 locations

SWOG Cancer Research NetworkPhase 2/3 NCT06616584 Registry history of NCT06616584 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Trial sites expanded: 266 → 278 locations

SWOG Cancer Research NetworkPhase 2 NCT06031688 Registry history of NCT06031688 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Trial sites expanded: 248 → 271 locations

SWOG Cancer Research NetworkPhase 2 NCT06116682 Registry history of NCT06116682 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams

Trial sites expanded: 1 → 7 locations

SWOG Cancer Research NetworkNot applicable NCT07278739 Registry history of NCT07278739 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

Adding Asciminib to Usual Treatment · Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Trial sites expanded: 11 → 16 locations

SWOG Cancer Research NetworkPhase 2 NCT06773936 Registry history of NCT06773936 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026
Minor

CAPT-HN · Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Trial sites expanded: 8 → 12 locations

SWOG Cancer Research NetworkPhase 2 NCT07062354 Registry history of NCT07062354 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026
Minor

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy · Cancer

Completion pushed from Sep 1, 2026 to Feb 1, 2027

SWOG Cancer Research NetworkNot specified NCT03939481 Registry history of NCT03939481 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Phase 4

Not charted: 9 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 58

NCT ID	Title	Condition	Status	Updated
Phase 4
NCT07498205	Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low…	Myelofibrosis	Not Yet Recruiting	2026-09-17
Phase 3
NCT03678025	Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants…	Castration Levels of Testosterone	Recruiting	2026-10-08
NCT04510597	Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without…	Metastatic Clear Cell Renal Cell Carcinoma	Recruiting	2026-10-08
NCT07383441	Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer	Advanced Clear Cell Renal Cell Carcinoma	Recruiting	2026-06-11
NCT05561387	Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a…	Plasma Cell Myeloma	Recruiting	2026-06-10
NCT06998940	Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or…	Locally Advanced Pancreatic Adenocarcinoma	Recruiting	2026-05-22
NCT05642611	Comparing Cooling and/or Compression Approaches of Limbs for Prevention of…	Malignant Solid Neoplasm	Recruiting	2026-05-06
NCT06022939	Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone…	AL Amyloidosis	Recruiting	2026-05-06
NCT06807437	Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a…	Pancreatic Carcinoma	Recruiting	2026-03-31
NCT07018869	Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC)…	Colorectal Cancer Stage II	Recruiting	2026-03-31
NCT06470243	Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will…	Castration-Resistant Prostate Carcinoma	Recruiting	2026-01-22
NCT05929768	Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative…	Anatomic Stage I Breast Cancer AJCC v8	Recruiting	2025-11-05
NCT03418961	S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+…	Cardiotoxicity	Recruiting	2025-10-08
NCT04071457	S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to…	Multiple Myeloma	Active, Not Recruiting	2026-09-17
NCT07802626	Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast…	HR Positive/HER-2 Negative Breast Cancer	Not Yet Recruiting	2026-09-03
NCT00070564	S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With…	Breast Cancer	Active, Not Recruiting	2026-08-28
NCT04155034	S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus…	Extensive Stage Lung Small Cell Carcinoma	Active, Not Recruiting	2026-06-11
NCT07220187	Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter…	Richter Syndrome	Not Yet Recruiting	2026-06-11
NCT02785952	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating…	Recurrent Squamous Cell Lung Carcinoma	Active, Not Recruiting	2026-06-09
NCT07615049	Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas…	Recurrent Soft Tissue Sarcoma of the Trunk and Extremities	Not Yet Recruiting	2026-05-29
NCT07578116	Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That…	Anatomic Stage IV Breast Cancer AJCC v8	Not Yet Recruiting	2026-05-27
NCT03757949	Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be…	Bladder Carcinoma	Active, Not Recruiting	2026-05-04
NCT05633602	Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent…	Recurrent Lung Non-Small Cell Carcinoma	Active, Not Recruiting	2026-04-17
NCT01349881	S0820, Adenoma and Second Primary Prevention Trial	Colorectal Neoplasms	Active, Not Recruiting	2026-04-02
NCT03091660	S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle…	Stage 0 Bladder Urothelial Carcinoma	Active, Not Recruiting	2026-03-23

SWOG Cancer Research Network clinical trial pipeline

What changed in the last 30 days

Standard Systemic Therapy With or Without Definitive Treatment · Metastatic Prostate Cancer

DRAMMATIC · S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment · Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams

Adding Asciminib to Usual Treatment · Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

CAPT-HN · Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy · Cancer

Active trials by phase

Active trials top 25 of 58

Disease areas by active trials, top 10 of 25